James Parkinson's disease was first described in 1817, as a chronic and progressive condition that impairs motor functions, muscle regulation, and stability. Since its classification over 200 years ago, it continuously ranks as one of the most prevalent neurodegenerative ailments linked to aging. This debilitating disease adversely affects the daily lives of more than 10 million individuals globally. Parkinson's disease is marked by a steady decline in neurons responsible for producing dopamine in the brain. Initial symptoms can be mild but typically progress to include shaking, stiffness, slowed motion (bradykinesia), and difficulties with balance and swallowing. As the disease advances, it can result in intensified motor and non-motor symptoms.
Historically, diagnosing Parkinson's disease has been challenging due to the absence of a specific test or biological marker. Diagnoses made on subjective clinical assessment of symptoms can vary significantly from one patient to another. This variability makes it difficult to monitor the disease's progression, as doctors often rely on reports from patients and their families. Furthermore, by the time Parkinson's disease is typically diagnosed, it has usually advanced to the stage where the patient exhibits the classical symptoms. These symptoms may develop well before diagnosis, as early symptoms are frequently dismissed as normal effects of aging or other medical conditions. Despite ongoing efforts, accurately pinpointing the initial stages of Parkinson's disease continues to be an imprecise endeavor.
Alpha-synuclein is an abundant protein in the brain, by some estimates it makes up about 1% of the brain's protein content. It is involved in managing the movement of synaptic vesicles and the release of neurotransmitters. Native alpha-synuclein exists as tetramers in equilibrium with unfolded monomers, however, mutations of this vital protein result in structural and conformational changes causing the alpha-synuclein monomers to aggregate and become insoluble. Testing for these aggregates is a reliable method for determining and monitoring the progression of their associated diseases.
As a biomarker for Parkinson's disease, alpha-synuclein is significant because it constitutes a large part of Lewy bodies (Figure 1). These are clumps of proteins that accumulate in the brains of those with Parkinson's disease. The accumulation of these Lewy bodies, which include misshapen alpha-synuclein, is a key indicator of the disease. Studies have indicated that testing spinal fluid for alpha-synuclein levels can assist in diagnosing individuals with Parkinson's disease.
Aside from Parkinson's disease, alpha-synuclein is implicated in a group of neurodegenerative conditions termed synucleinopathies. This category encompasses disorders such as dementia with Lewy bodies (DLB), multiple system atrophy (MSA), pure autonomic failure (PAF), and REM sleep behavior disorder (RBD). All these conditions share a characteristic trait: the unusual buildup of alpha-synuclein within the nervous system, which plays a role in the development of these diseases.
The development of the alpha-synuclein seed amplification assay marked a significant advancement in the detection and ongoing observation of Parkinson's disease. By identifying the presence of misfolded alpha-synuclein proteins, a known biomarker of Parkinson's, the assay can pinpoint the condition from its initial stages. The assay tests the patient's spinal fluid, taken by a lumbar puncture, for the presence of alpha-synuclein clumps. The test is sensitive enough to detect individuals at risk for Parkinson's. It demonstrates high sensitivity and specificity rendering it an invaluable instrument for the early identification and continual monitoring of the development of the disease.
Silica beads (OPS Diagnostics) are essential in the alpha-synuclein seed amplification assay as they significantly aid the amplification process (Figure 2). A team of researchers from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana used silica beads (0.8 mm, OPS Diagnostics) for this application to agitate the solution. These beads (6 to 8 beads are strategically placed in the assay plate wells) specifically target and encourage alpha-synuclein proteins to clump together, providing a conducive environment for the formation of amyloid fibrils. The aggregation process is then tracked with thioflavin T, a fluorescent dye that attaches to the amyloid fibrils rich in beta-sheets, causing a fluorescence increase that signals the accumulation of alpha-synuclein. The alpha-synuclein seed amplification assay has evolved from a concept in the 1990s for detecting prion diseases, which has been refined as a diagnostic tool for Parkinson's disease. Initially, it was adapted to identify misfolded alpha-synuclein proteins. By the 2010s, it showed potential as a biomarker for early Parkinson's detection. In the 2020s, after further refinement and validation, this assay became essential in clinical research for diagnosing and monitoring Parkinson's disease. The decision to utilize several silica beads strikes a balance between achieving a satisfactory thioflavin T signal intensity and the practicality of arranging the plates. Therefore, the incorporation of silica beads is pivotal for the assay's ability to detect these critical protein aggregates early with high accuracy (about 87.7% of the time) and enhanced sensitivity.
In summary, the beads from OPS Diagnostics are a key component of the alpha-synuclein seed amplification assay, offering a solid foundation for the prompt and precise detection of Parkinson's disease, which in turn supports improved results for patients. While there is still no cure, early detection of Parkinson's disease is crucial for earlier intervention in managing symptoms and improving the quality of life for those affected.
AlMahadin, G., Lotfi, A., Zysk, E., Siena, F. L., Carthy, M. M., & Breedon, P. (2020). Parkinson's disease: current assessment methods and wearable devices for evaluation of movement disorder motor symptoms - a patient and healthcare professional perspective. BMC Neurology, 20(1). https://doi.org/10.1186/s12883-020-01996-7
Bargar, C., Wang, W., Gunzler, S. A., LeFevre, A., Wang, Z., Lerner, A. J., Singh, N., Tatsuoka, C., Appleby, B. S., Zhu, X., Xu, R., Haroutunian, V., Zou, W.-Q., Ma, J., and Chen, S. G. 2021. Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathologica Communications. 9 Hurwitz B. Urban observation and sentiment in James Parkinson's Essay on the Shaking Palsy (1817). Lit Med. 2014 Spring;32(1):74-104. doi: 10.1353/lm.2014.0002. PMID: 25055707; PMCID: PMC4077538
Caughey, B. 2023. ?-Synuclein seeding activity in duodenum biopsies from Parkinson's disease patients. PLOS Pathogens. 19:e1011456
Concha, M. L., Farris, C. M., Holguin, B., Ma, Y., Seibyl, J., Russo, M. J., Kang, U. J., Hutten, S. J., Merchant, K., Shahnawaz, M., & Soto, C. (2021). Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression. Movement Disorders, 36(10), 2444-2446. https://doi.org/10.1002/mds.28715
Concha-Marambio, L., Pritzkow, S., Shahnawaz, M., Farris, C. M., & Soto, C. (2023). Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid. Nature Protocols, 18(4), 1179-1196. https://doi.org/10.1038/s41596-022-00787-3
Kim WS, Kågedal K, Halliday GM. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther. 2014 Oct 27;6(5):73. doi: 10.1186/s13195-014-0073-2. PMID: 25580161; PMCID: PMC4288216.
Parkinson's test (a-Synuclein seed amplification assay) - Mayo Clinic https://www.mayoclinic.org/tests-procedures/parkinsons-testing-alpha-synuclein-seed-amplification/about/pac-20556191 (accessed May 15, 2024)
O'Leary, K. D. (2023). Biomarker study a game-changer for Parkinson's disease. Nature Medicine. https://doi.org/10.1038/d41591-023-00039-1
Saijo, E., Groveman, B. R., Kraus, A., Metrick, M. A., Orrú, C. D., Hughson, A. G., and Caughey, B. 2018. Ultrasensitive RT-QUIC seed amplification assays for Disease-Associated TAU, ?-Synuclein, and Prion aggregates. Pages 19-37 in: Methods in molecular biology
Shahnawaz, M., Tokuda, T., Waragai, M., Mendez, N., Ishii, R., Trenkwalder, C., Mollenhauer, B., & Soto, C. (2017). Development of a biochemical diagnosis of Parkinson disease by detection of ?-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurology, 74(2), 163-172. https://doi.org/10.1001/jamaneurol.2016.4547
